• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有多个二元终点的配对设计的样本量确定与重新估计

Sample size determination and re-estimation for matched pair designs with multiple binary endpoints.

作者信息

Xu Jin, Yu Menggang

机构信息

Department of Statistics and Actuarial Science, East China Normal University, Shanghai, 200241, China.

出版信息

Biom J. 2013 May;55(3):430-43. doi: 10.1002/bimj.201100231. Epub 2013 Apr 2.

DOI:10.1002/bimj.201100231
PMID:23553605
Abstract

Motivated by a recent symptom management trial to simultaneously assess multiple binary endpoints for cancer chemotherapy, we extend the univariate McNemar test to multivariate cases for doubly blinded clinical trials with matched pairs. We propose a general method to test noninferiority or equivalence. The method employs the intersection-union principle on the marginal score statistics to obtain an asymptotic α-level test. Power formula and sample size calculation are provided by a simple numerical method that accounts for the correlation structure among the endpoints. We further consider sample size re-estimation through internal pilot study. To avoid the need of unblinding for doubly blinded trials, we also propose a blinded approach for nuisance parameter estimation. The effectiveness of the proposed methods is demonstrated by simulation studies. Application to the cancer chemotherapy trial is illustrated.

摘要

受近期一项针对癌症化疗同时评估多个二元终点的症状管理试验的启发,我们将单变量麦克尼马尔检验扩展到多变量情形,用于配对双盲临床试验。我们提出了一种检验非劣效性或等效性的通用方法。该方法在边际得分统计量上采用交并原则以获得渐近α水平检验。通过一种考虑终点间相关结构的简单数值方法提供了功效公式和样本量计算。我们进一步考虑通过内部预试验进行样本量重新估计。为避免双盲试验中揭盲的需要,我们还提出了一种用于干扰参数估计的盲法。模拟研究证明了所提方法的有效性。文中还举例说明了该方法在癌症化疗试验中的应用。

相似文献

1
Sample size determination and re-estimation for matched pair designs with multiple binary endpoints.具有多个二元终点的配对设计的样本量确定与重新估计
Biom J. 2013 May;55(3):430-43. doi: 10.1002/bimj.201100231. Epub 2013 Apr 2.
2
Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in variance estimation.优效性和非劣效性试验中的盲法样本量重新估计:方差估计中的偏差与方差
Pharm Stat. 2013 May-Jun;12(3):141-6. doi: 10.1002/pst.1564. Epub 2013 Mar 19.
3
Variance estimation in clinical studies with interim sample size re-estimation.在进行中期样本量重新估计的临床研究中的方差估计。
Biometrics. 2005 Jun;61(2):355-61. doi: 10.1111/j.1541-0420.2005.00315.x.
4
Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.盲法样本量重估与计数数据:多发性硬化中的方法与应用。
Stat Med. 2010 May 10;29(10):1145-56. doi: 10.1002/sim.3861.
5
Blinded sample size re-estimation in crossover bioequivalence trials.交叉生物等效性试验中的盲法样本量重新估计
Pharm Stat. 2014 May-Jun;13(3):157-62. doi: 10.1002/pst.1617. Epub 2014 Apr 9.
6
Blinded and unblinded internal pilot study designs for clinical trials with count data.针对计数数据临床试验的盲法和非盲法内部预试验设计。
Biom J. 2013 Jul;55(4):617-33. doi: 10.1002/bimj.201200189. Epub 2013 May 24.
7
Sample size re-estimation for survival data in clinical trials with an adaptive design.具有适应性设计的临床试验中生存数据的样本量重新估计。
Pharm Stat. 2011 Jul-Aug;10(4):325-31. doi: 10.1002/pst.469. Epub 2010 Oct 28.
8
Multiple-arm superiority and non-inferiority designs with various endpoints.具有多种终点的多臂优效性和非劣效性设计。
Pharm Stat. 2007 Jan-Mar;6(1):43-52. doi: 10.1002/pst.242.
9
Blinded sample size re-estimation in three-arm trials with 'gold standard' design.采用“金标准”设计的三臂试验中的盲法样本量重新估计。
Stat Med. 2017 Oct 15;36(23):3636-3653. doi: 10.1002/sim.7356. Epub 2017 Jun 12.
10
Sample size re-estimation incorporating prior information on a nuisance parameter.纳入关于干扰参数的先验信息的样本量重新估计。
Pharm Stat. 2018 Mar;17(2):126-143. doi: 10.1002/pst.1837. Epub 2017 Nov 27.

引用本文的文献

1
Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.使用多个共同主要二元相对风险对比比较两种干预措施时临床试验中的样本量考量
Stat Biopharm Res. 2015 Jun 24;7(2):81-94. doi: 10.1080/19466315.2015.1006373.